News >

Immunotherapy Trials Offer Hope in Advanced Penile Cancer

Angelica Welch
Published: Tuesday, Feb 20, 2018

Guru Sonpavde, MD

Guru Sonpavde, MD
Penile cancer is a historically poor-prognosis disease, with patients who progress following chemotherapy having little to no effective options. This needs to change, says Guru Sonpavde, MD, starting with replacing the standard of care with novel regimens being explored in clinical trials.

Sonpavde, director of Bladder Cancer at Dana-Farber Cancer Institute, discussed the importance of clinical trial enrollment for patients with penile cancer and shared his insight on immunotherapy research in this setting.

OncLive: Can you discuss the treatment and management of this population?

Sonpavde: Patients with metastatic or advanced penile squamous cell carcinoma have a very poor prognosis with current chemotherapy. This consists of cisplatin-based combinations, including cisplatin plus 5-fluorouracil and sometimes 3-drug combinations, such as ifosfamide, paclitaxel, and cisplatin. However, we know that the median survival with these cisplatin-based combination regimens is approximately in the 8- to 9-month range, so it’s quite dismal. Most patients will progress and fail; that is when we get into the salvage options, results of which are even more dismal.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Clinical Practice Connections™: New York Advanced Practice CollaborativeNov 15, 20191.25
Publication Bottom Border
Border Publication
x